Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial-Reference-Cited by-同舟云学术

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Published:2022-11 Issue: Volume:85 Page:104298
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Madhavan Meera,Ritchie Adam J.,Aboagye Jeremy,Jenkin Daniel^ORCID,Provstgaad-Morys Samuel,Tarbet Iona,Woods Danielle,Davies Sophie,Baker Megan,Platt Abigail,Flaxman Amy,Smith Holly,Belij-Rammerstorfer Sandra,Wilkins Deidre,Kelly Elizabeth J.,Villafana Tonya,Green Justin A.,Poulton Ian,Lambe Teresa,Hill Adrian V.S.,Ewer Katie J.,Douglas Alexander D.^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference46 articles.

1. Ponce-de-Leon S, Torres M, Soto-Ramirez LE, et al. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: interim results of a non-randomized open label phase I trial in Mexico. medRxiv. 2022.

2. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials;Zhu;Lancet Respir Med,2022

3. Intranasal COVID-19 vaccines: from bench to bed;Alu;EBioMedicine,2022

4. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial;Wu;Lancet Infect Dis,2021

5. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial;Li;Lancet Respir Med,2022

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates;Nature Immunology;2024-09-03

2. Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer;Molecular Therapy - Nucleic Acids;2024-09

3. Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial;Vaccines;2024-09-01

4. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters;Frontiers in Immunology;2024-08-30

5. Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges;ACS Nano;2024-08-26